Biotech | October 04, 2022
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Construction is now underway with the facility scheduled to be operational by 2025
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Roy is the right successor to lead Philips’ efforts to help improve the health and well-being of people globally
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The company will address the observations within a stipulated timeline working with the regulators
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Subscribe To Our Newsletter & Stay Updated
